

小动物活体光学成像技术在感染性疾病研究中的应用

Revivity小动物活体光学成像技术已在生命科学基础研究、临床前医学研究及药物研发等领域得到广泛应用。在众多应用领域中，感染性疾病研究是活体光学成像技术的应用热点之一。在应用活体光学成像技术进行感染性疾病研究中，常用的标记方法及应用领域包括：1、利用萤火虫荧光素酶基因、海肾荧光素酶基因或细菌荧光素酶基因标记细菌、病毒、真菌、寄生虫等病原体，在活体水平观测这些病原体在动物体内的感染情况及抗生素、疫苗等药物的治疗效果；2、通过荧光素酶基因或荧光蛋白基因标记免疫细胞，以及利用特定基因-荧光素酶基因转基因动物，观测病原体感染所引发的机体免疫应答及致病机理。下面结合一些具体实例进行阐述：

一.长时间观测病原体在动物体内的动态感染情况


利用 PCR、免疫切片等传统方法对感染性疾病进行研究时，需要耗费大量的人力物力，且不能实现在同一只活体小鼠中长期观测病原体的动态感染情况，因而无法获得准确的重复性数据。小动物活体光学成像技术的出现，使得研究者能够通过一定的方式对细菌、病毒、真菌、寄生虫等病原体进行光学标记，并利用活体光学成像系统长期观测病原体在体内的动态感染情况，在节省实验耗材及简化实验操作的同时，可获得更加直观准确的实验结果。

在观测细菌感染方面，研究者既可利用萤火虫荧光素酶基因、海肾荧光素酶基因等常用于标记真核细胞的报告基因进行标记，也可利用从某些发光细菌中提取的 lux 发光基因操纵子进行标记。后者的好处是，lux 操纵子中已含有表达荧光素酶及其底物的序列，因此无需再外源注射底物即可成像。Revivity提供多种商业化的经细菌荧光素酶基因标记的生物发光细菌菌种（如下图所示）：


菌种名称	菌种来源	货号	菌种名称	菌种来源	货号
大肠杆菌	EPEC WS2572	119223	肺炎链球菌	D39 Serotype 2	119245
	ETEC WS2583	119225		HUS-TMBIG, Serotype 19A	119246
流感嗜血杆菌	ATCC 51907	119224		A66.1, Serotype 3	119247
	肺炎克雷伯菌	93A 5370		119227	EF3030, Serotype 19F
ATCC 23074		119237		140301, Serotype 14	119249
李斯特菌	10403S (Serotype 1/2a wild-type strain)	119238	肺炎链球菌	230401	119321
绿脓杆菌	ATCC 19660	119228	Serotype 23		
	PAO1	119229	肺炎链球菌	TIGR Strain	119322
奇异变形杆菌	ATCC 51286	119236	Serotype 4		
金黄色葡萄球菌	8325-4	119239	产脓链球菌	Strain 591, Group A, Serotype M49	119250
	ATCC 12600	119240	鼠伤寒沙门菌	SL1344	119230
	16-MRSA	119241	FDA1189		119235
	ATCC 33591	119242	小肠结肠炎耶尔森菌	91A1854 Clinical isolate	119232
	ATCC 49525	119243		WS2589	119233
痢疾杆菌	UAMS-1	119244	假结合性桿菌	YP111pYV (Type III secretion system), clinical isolate	119234
	88A6205. Clinical isolate	119231			

研究者通过购买这些生物发光细菌，即可立即开展相关研究，无需自行标记。如 Hardy 等利用 IVIS 系统观测了细菌荧光素酶基因标记的单核细胞增多性李斯特菌

(*Listeria monocytogenes*) 在小鼠体内的时空分布，如下图：




上图：应用 IVIS 系统观测不同时间点李斯特菌在小鼠体内的感染情况。A.尾静脉注射；B.口腔注射。研究者在通过尾静脉注射李斯特菌感染多只小鼠后发现，几乎在所有被感染小鼠中，该细菌都会特异性分布于小鼠胸部，经手术将发光组织取出后发现，细菌主要集中于胆囊内腔（the lumen of the gall bladder），如下图所示。细菌在胆囊内腔的存留是一个非常危险的信号，因为胆囊内腔由于含有高浓度的胆汁而导致免疫细胞无法进入发挥免疫保护作用，并且胆囊本身又对抗生素具有抵抗性，因此，细菌可以在此区域长期潜伏并随时发作。



上图：应用 IVIS 系统观测到李斯特菌在胆囊内腔的特异性分布。左：感染 25 只小鼠，在 24 只中观测到李斯特菌在胆囊内腔的分布；右：将胸部发光组织取出后确认为胆囊内腔。


研究者接下来探讨了李斯特菌在胆囊内腔的分布是否具有传染性。由于胆囊在机体未进食时会大量存储由肝脏分泌的胆汁而处于扩张状态，而当机体进食后，胆囊会收缩并将胆汁通过胆管排入小肠而辅助对食物中的脂肪进行消化。因此，研究者通过对被感染的小鼠禁食后再喂食，观测李斯特菌是否能够通过胆汁排泄途径而进入消化道。结果显示，李斯特菌确实能够通过胆汁排泄途径而进入小肠（如下图），并可能通过消化道的排泄进入外界环境而具有传染性。综上所述，研究者利用活体光学成像技术，系统的研究了李斯特菌在小鼠体内的感染分布、潜伏及潜在的传染途径，为该类疾病的治疗提供了依据。

BLI of *L. monocytogenes* in mice after fasting and feeding




上图:应用 IVIS 系统观测李斯特菌经胆汁排泄途径由胆囊进入消化道。B、C 分别为再喂食后 5min 及 50min 成像结果。

对细菌生物膜 (Bacterial Biofilm) 的研究也是细菌感染研究的一大热点。细菌生物膜是细菌在生长过程中附着于物体表面而形成的由细菌细胞及其分泌的含水聚合性基质 (主要为胞外多糖) 等所组成的膜样多细菌复合体。生物膜是细菌适应生存环境而形成的与游走态细胞相对应的存在形式, 它具有很强的抵抗机体免疫和抗生素的能力, 在临床上形成难治性感染。Bernthal 等通过在小鼠下肢股骨远端插入接种了生物发光金黄色葡萄球菌 (*S. aureus*) 的不锈钢针, 模拟了人关节成形手术后经常发生的细菌生物膜形成, 并用 IVIS 系统及变压扫描电镜 (VP-SEM) 观测了细菌感染及生物膜的形成 (如下图)。这种实验模型的建立为开发有效的治疗手段及抗菌剂提供了有力工具。




上图: 通过模拟实验观测关节成形术后 *S. aureus* 的感染及生物膜的形成。A. 模拟实验示意图及钢针移植后 X 光成像结果; B. 应用 IVIS 系统观测不同数量生物发光 *S. aureus* 在关节处的感染情况; C. 应用 VP-SEM 观测细菌生物膜的形成。

在病毒研究方面，研究者通常将萤火虫荧光素酶基因插入病毒 DNA 中标记病毒，进而观测病毒在活体动物体内的动态变化。Milho 等人利用 IVIS 系统观测比较了经不同途径感染小鼠的鼠源疱疹病毒（murine herpesvirus-4, MuHV-4）在小鼠体内的感染分布情况。结果显示，经鼻腔感染的病毒，在感染早期主要分布于小鼠的鼻腔及肺，随着时间的延长，病毒将集中分布于颈部淋巴结及脾等淋巴组织；经腹腔接种的病毒，在感染早期分布于腹部的多个器官（如肝、脾、肾、肠、生殖系、隔膜），所时间的延长，病毒将集中分布于脾及肠系膜淋巴结。因此，病毒的不同感染途径可能会引起不同的发病机制。




上图：应用 IVIS 系统观测 MuHV-4 病毒经不同途径接种后的感染情况。上，活体成像结果；下，将不同器官取出后体外成像结果。

与细菌、病毒感染研究类似，研究者也可通过荧光素酶基因标记寄生虫，观测其在活体动物体内的感染情况。如 Claes 等人利用 IVIS 系统观测了经海肾荧光素酶基因标记的布氏锥虫 (*Trypanosoma brucei*) 在小鼠体内的感染情况。体内及体外成像结果显示，经腹注射后，布氏锥虫选择性分布于睾丸。布氏锥虫在睾丸的选择性分布可能会使其避开药物的作用，因为许多药物无法通过睾丸-血管屏障而进入睾丸。随后的给药实验印证了这种推断，在布氏锥虫感染小鼠 5 天后，用虫草素 (cordycepin) 连续进行三天处理，停药后在第 15 天发现睾丸处重新出现布氏锥虫生物发光信号。这一研究为开发治疗布氏锥虫感染的有效药物提供了依据。



上图：应用 IVIS 系统观测布氏锥虫在小鼠体内的感染情况。左，感染后不同时间点活体成像结果；右上，取出睾丸后体外成像结果；右下，虫草素对布氏锥虫的治疗效果观测。

近些年，研究者也开始利用荧光素酶基因标记真菌，并通过活体光学成像系统观测真菌在动物体内的感染情况。Doyle 等人应用萤火虫荧光素酶基因标记了从临床病例中获得的白色念珠菌 (*Candida albicans*)，将该真菌尾静脉注射入小鼠体内构建慢性败血症感染模型，利用 IVIS 系统观测了生物发光白色念珠菌在小鼠体内的感染情况。体内及体外成像结果显示，随感染时间的延长，该菌主要分布于小鼠肾脏（如下图）。




上图：应用 IVIS 系统观测白色念珠菌经尾静脉注射后在小鼠体内的感染情况。A.体内成像结果；B.体外成像结果。

二.监测抗感染免疫反应


在利用小动物活体光学成像技术观测病原体在动物体内感染情况的同时，还可应用该技术观测机体对病原体入侵的免疫反应。此类应用可以通过三种方式实现：1、利用报告基因标记在免疫细胞中特异性表达的基因启动子而构建转基因动物，以该转基因动物为实验模型，用经光学标记的病原体对其进行感染，观测病原体感染而引发的免疫细胞应答；2、利用报告基因标记目的基因的启动子构建转基因动物，观测病原体感染后该基因的表达情况，了解免疫应答的分子机理；3、利用某种免疫相关基因被敲除的基因敲除鼠作为实验模型，观测病原体的感染情况，以了解这些基因在免疫反应中的作用。

Cho 等利用 LysEGFP 转基因小鼠作为实验用鼠，应用 IVIS 系统观测了生物发光金黄色葡萄球菌经皮肤伤口感染小鼠后引发的嗜中性粒细胞的免疫应答。由于实验小鼠是 LysEGFP 转基因小鼠，因此其体内的嗜中性粒细胞即为 EGFP 所标记，因此在使用生物发光成像模式观测细菌感染的同时，也能通过荧光成像模式观测嗜中性粒细胞在感染部位的聚集。如下图所示，与未经感染的对照组相比，金黄色葡萄球菌的感染引发了大量嗜中性粒细胞在感染部位的聚集，这伴随着细菌感染程度相应地降低，而对对照组中少量嗜中性粒细胞的聚集是由于皮肤创伤而引起的免疫反应。




上图：应用 IVIS 系统观测生物发光金黄色葡萄球菌对 LysEGFP 转基因小鼠皮肤伤口的感染及所引起的嗜中性粒细胞的免疫应答情况。左，不同时间点金黄色葡萄球菌感染生物发光成像及定量结果；右，EGFP 标记的嗜中性粒细胞对细菌感染的应答荧光成像及定量结果。

IL-1R 信号通路的激活在嗜中性粒细胞对金黄色葡萄球菌皮肤感染的免疫应答中起重要调控作用，而 IL-1 α 和 IL-1 β 是激活 IL-1R 信号通路的两种主要配体。Miller 等人通过应用敲除上述两种基因的基因缺陷型小鼠 IL-1 $\alpha^{-/-}$ 、IL-1 $\beta^{-/-}$ 及 IL-1 α /IL-1 $\beta^{-/-}$ ，揭示了 IL-1 β 在趋化嗜中性粒细胞到达皮肤感染区域所起的重要调控作用。结果显示，金黄色葡萄球菌对野生型小鼠及 IL-1 $\alpha^{-/-}$ 缺陷型小鼠中的感染程度相当，而对 IL-1 $\beta^{-/-}$ 及 IL-1 α /IL-1 $\beta^{-/-}$ 缺陷型小鼠的感染程度明显高于前两者，说明 IL-1 β 在趋化嗜中性粒细胞对金黄色葡萄球菌皮肤感染的免疫应答中是必须的。




上图：应用 IVIS 系统观测生物发光金黄色葡萄球菌对野生型小鼠及三种基因缺陷型小鼠 IL-1 $\alpha^{-/-}$ 、IL-1 $\beta^{-/-}$ 和 IL-1 α /IL-1 $\beta^{-/-}$ 的皮肤感染情况。左，普通相机拍摄图片；右，活体光学成像结果。

Cheeran 等利用从转基因小鼠 Tg(β -actin-luc)中提取的脾细胞及淋巴结细胞，研究了免疫细胞对病毒感染的响应。研究者将提取的发光脾细胞及淋巴结细胞通过尾静脉注入脑室内感染巨细胞病毒的小鼠，利用 IVIS 系统观测了上述免疫细胞在活体动物体内对感染病灶点的浸润。结果显示，在未经病毒感染的正常小鼠体内，移植的淋巴细胞主要聚集于脾内（如下图-1dpi 所示），而当小鼠脑部感染病毒后，这些淋巴细胞会迁移至感染区域而发挥免疫清除作用。



上图：利用 IVIS 系统观测免疫细胞对病毒感染的免疫应答。A、小鼠背部朝上拍摄；B、小鼠腹部朝上拍摄。-1dpi 为病毒感染前 24h 尾静脉注射淋巴细胞成像结果，每张图中从左至右第一只小鼠为注射生理盐水的对照小鼠，第二、三只小鼠为脑室内感染巨细胞病毒的疾病小鼠。

Davies 等利用嗜酸性粒细胞特异性启动子 EPX 控制萤火虫荧光素酶基因的表达，而构建了转基因小鼠 EPX-luc，并用该转基因小鼠作为实验小鼠，观测了由血吸虫（Schistosome）感染而引发的嗜酸性粒细胞的免疫应答。结果显示，在感染后 8 至 10 周，嗜酸性粒细胞主要在肝脏、小肠、上下肢及胸骨中增多，而这种增多是由血吸虫卵在这些区域的沉积所引发，而血吸虫自身也会在早期潜伏性感染时引起小肠中嗜酸性粒细胞的增多。




上图：利用 IVIS 系统观测嗜酸性粒细胞对血吸虫感染的免疫应答。A、EPX-luc 表达载体构建示意图；B、感染 70 天后活体成像结果及 ROI 圈选示意图；C、不同时间点由于血吸虫感染而引发的嗜酸性粒细胞在不同部位增多的活体成像结果；D、感染后不同时间点不同部位（肝、小肠、上肢及胸骨、下肢）嗜酸性粒细胞活体成像定量结果。

三. 抗生素及疫苗等抗感染药物研发


应用传统方式对抗生素、疫苗等抗感染药物在活体水平的研发筛选，需要在给药后处死小鼠，取出感染部位，再通过 PCR、菌落计数、切片观察等方法对药物治疗效果进行评价。这些方式需要耗费大量实验动物、进行繁琐的实验操作，很难实现高通量筛选，且不能利用同一只动物从头到尾的获取实验数据，因此很难获取准确的重复性数据。小动物活体光学成像技术是一种非侵入式活体观测技术，无需在实验过程中处死老鼠，并且可以使用同一批老鼠完成不同时间点的观测，因此已广泛应用于抗感染药物的研发。

抗生素 (antibiotics) 是由微生物 (包括细菌、真菌、放线菌属) 或高等动植物在生活过程中所产生的具有抗病原体或其它活性的一类次级代谢产物，可用于治疗各种细菌感染或抑制致病微生物的感染。应用小动物活体光学成像技术可以评价抗生素对病原体感染的治疗效果。达托霉素 (Daptomycin/Cubicin) 是 Cubist Pharmaceuticals 制药公司研发的已获得 FDA 认证的一种抗生素类药物，可用于革兰氏阳性菌感染而导致的腹膜炎的治疗。该公司在此药物的研发过程中即应用到了小动物活体光学成像技术以评价该抗生素对腹膜炎的治疗效果。研究者应用生物发光金黄色葡萄球菌 (*S. aureus*) 通过腹腔注射感染小鼠诱发腹膜炎，之后比较了 Daptomycin、Vancomycin 及 Linezolid 三种抗生素对细菌感染的抑制效果。结果显示，Daptomycin 的治疗效果最好，如下图：



上图：利用 IVIS 系统观测 Daptomycin (50 mg/kg)、Vancomycin (100 mg/kg) 及 Linezolid (100 mg/kg) 三种抗生素对金黄色葡萄球菌感染的抑制效果。

疫苗是将病原微生物（如细菌、立克次氏体、病毒等）及其代谢产物，经过人工减毒、灭活或利用基因工程等方法制成的用于预防传染病的自动免疫制剂。疫苗保留了病原菌刺激动物体免疫系统的特性。当动物体接触到这种不具伤害力的病原菌后，免疫系统便会产生一定的保护物质，如免疫激素、活性生理物质、特殊抗体等；当动物再次接触到这种病原菌时，动物体的免疫系统便会依循其原有的记忆，制造更多的保护物质来阻止病原菌的伤害。应用小动物活体光学成像技术可以评价疫苗对病原体感染的治疗效果。Karanam 等应用 IVIS 系统观测了联合使用 TA-CIN 疫苗及 GPI-0100 辅药对小鼠预防性接种后，对荧光素酶基因标记的人乳头瘤假病毒 HPV16 皮肤感染的预防治疗效果。结果显示，与单独接种相比，TA-CIN 疫苗及 GPI-0100 辅药的联合使用能够更好的抑制人乳头瘤假病毒的感染，其中 GPI-0100 辅药在诱导体液及细胞免疫应答方面发挥重要作用。



上图：利用 IVIS 系统观测联合使用 TA-CIN 疫苗及 GPI-0100 辅药对 HPV16 感染的预防抑制效果。

IVIS APPLICATIONS IN INFECTIOUS DISEASE RESEARCH

1. Ahlen G, Weiland M, Derk E, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grander D, Frelin L, Sallberg M. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. *Gut*. Aug 19 2008.
2. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. *Proc Natl Acad Sci U S A*. Apr 15 2008;105(15):5850-5855.
3. Amante FH, Stanley AC, Randall LM, Zhou Y, Haque A, McSweeney K, Waters AP, Janse CJ, Good MF, Hill GR, Engwerda CR. A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. *The American journal of pathology*. Aug 2007;171(2):548-559.
4. Anderson MZ, Brewer J, Singh U, Boothroyd JC. A pseudouridine synthase homologue is critical to cellular differentiation in *Toxoplasma gondii*. *Eukaryotic cell*. Mar 2009;8(3):398-409.
5. Aravalli RN, Hu S, Woods JP, Lokensgard JR. Histoplasma capsulatum yeast phase-specific protein Yps3p induces Toll-like receptor 2 signaling. *Journal of neuroinflammation*. 2008;5:30.
6. Asgharpour A, Gilchrist C, Baba D, Hamano S, Hout E. Resistance to Intestinal Entamoeba histolytica Infection Is Conferred by Innate Immunity and Gr-1+ Cells. *Infect. Immun*. August 1, 2005 2005;73(8):4522-4529.
7. Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O'Toole T, Kraal G, Limmer A, den Haan JM. Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. *Proc Natl Acad Sci U S A*. Jan 5 2010;107(1):216-221.
8. Bahey-EI-Din M, Casey PG, Griffin BT, Gahan CG. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model. *Vaccine*. Sep 26 2008;26(41):5304-5314.
9. Bao S, Liu MJ, Lee B, Besecker BY, Lai JP, Guttridge DC, Knoell DL. Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF- κ B. *American journal of physiology*. Mar 5 2010.
10. Barendt SM, Land AD, Sham LT, Ng WL, Tsui HC, Arnold RJ, Winkler ME. Influences of capsule on cell shape and chain formation of wild-type and pcsB mutants of serotype 2 Streptococcus pneumoniae. *Journal of bacteriology*. May 2009;191(9):3024-3040.
11. Begley M, Bron PA, Heuston S, Casey PG, Englert N, Wiesner J, Jomaa H, Gahan CG, Hill C. Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection. *Infect Immun*. Nov 2008;76(11):5392-5401.

12. Begley M, Kerr C, Hill C. Exposure to bile influences biofilm formation by *Listeria monocytogenes*. *Gut pathogens*. 2009;1(1):11.
13. Benaron DA, Contag PR, Contag CH. Imaging brain structure and function, infection and gene expression in the body using light. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*. June 1997;352(1354):755-761.
14. Bergstrom KS, Guttman JA, Rumi M, Ma C, Bouzari S, Khan MA, Gibson DL, Vogl AW, Vallance BA. Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen. *Infect Immun*. Feb 2008;76(2):796-811.
15. BitMansour A, Burns SM, Traver D, Akashi K, Contag CH, Weissman IL, Brown JM. Myeloid progenitors protect against invasive aspergillosis and *Pseudomonas aeruginosa* infection following hematopoietic stem cell transplantation. *Blood*. December 2002;100(13):4660-4667.
16. Boyle JP, Saeij JP, Boothroyd JC. *Toxoplasma gondii*: Inconsistent dissemination patterns following oral infection in mice. *Exp Parasitol*. Jan 25 2007.
17. Brader P, Stritzker J, Riedl CC, Zanzonico P, Cai S, Burnazi EM, Ghani ER, Hricak H, Szalay AA, Fong Y, Blasberg R. *Escherichia coli* Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging. *Clin Cancer Res*. Mar 27 2008.
18. Brock M, Jouvion G, Droin-Bergere S, Dussurget O, Nicola MA, Ibrahim-Granet O. Bioluminescent *Aspergillus fumigatus*, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis. *Applied and environmental microbiology*. Nov 2008;74(22):7023-7035.
19. Burgos JS. Noninvasive bioluminescent imaging of infections. *Methods Mol Biol*. 2009;574:115-124.
20. Burgos JS, Guzman-Sanchez F, Sastre I, Fillat C, Valdivieso F. Non-invasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection. *Microbes and Infection*. 2006;8(5):1330-1338.
21. Burns SM, Joh D, Francis KP, Shortliffe LD, Gruber CA, Contag PR, Contag CH. Revealing the spatiotemporal patterns of bacterial infectious diseases using bioluminescent pathogens and whole body imaging. *Contributions to Microbiology*. 2001;9:71-88.
22. Burns SM, Olomu IN, Zhao H, Wong RJ, Stevenson DK, Contag CH. Monitoring Age-Related Susceptibility of Young Mice to Oral *Salmonella enterica* Serovar Typhimurium Infection Using an In Vivo Murine Model. *Pediatric Research*. March 2005.
23. Chatterjea D, Burns-Guydish SM, Sciuto TE, Dvorak A, Contag CH, Galli SJ. Adoptive transfer of mast cells does not enhance the impaired survival of KitW/KitW-v mice in a model of low dose intraperitoneal infection with bioluminescent *Salmonella typhimurium*. *Immunology Letters*. 2005;99(1):122-129.
24. Claes F, Vodnala SK, van Reet N, Boucher N, Lunden-Miguel H, Baltz T, Goddeeris BM, Buscher P, Rottenberg ME. Bioluminescent Imaging of

- Trypanosoma brucei Shows Preferential Testis Dissemination Which May Hamper Drug Efficacy in Sleeping Sickness. *PLoS neglected tropical diseases*. 2009;3(7):e486.
25. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. *Molecular Microbiology*. November 1995;18(4):593-603.
 26. Contag PR. Bioluminescence imaging to evaluate infections and host response in vivo. *Methods Mol Biol*. 2008;415:101-118.
 27. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. *Nature Medicine*. February 1998;4(2):245-247.
 28. Cook SH, Griffin DE. Luciferase imaging of a neurotropic viral infection in intact animals. *Journal of Virology*. May 2003;77(9):5333-5338.
 29. Costes B, Stalin Raj V, Michel B, Fournier G, Thirion M, Gillet L, Mast J, Lieffrig F, Bremont M, Vanderplasschen A. The major portal of entry of koi herpesvirus in cyprinus carpio is the skin. *J Virol*. Jan 19 2009.
 30. Cotter PD, Draper LA, Lawton EM, Daly KM, Groeger DS, Casey PG, Ross RP, Hill C. Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage I *Listeria monocytogenes*. *PLoS Pathog*. 2008;4(9):e1000144.
 31. Crawford MA, Zhu Y, Green CS, Burdick MD, Sanz P, Alem F, O'Brien AD, Mehrad B, Strieter RM, Hughes MA. Antimicrobial effects of interferon-inducible CXC chemokines against *Bacillus anthracis* spores and bacilli. *Infect Immun*. Apr 2009;77(4):1664-1678.
 32. Cronin M, Sleator RD, Hill C, Fitzgerald GF, van Sinderen D. Development of a luciferase-based reporter system to monitor *Bifidobacterium breve* UCC2003 persistence in mice. *BMC microbiology*. 2008;8:161.
 33. Davies SJ, Smith SJ, Lim KC, Zhang H, Purchio AF, McKerrow JH, West DB. In vivo imaging of tissue eosinophilia and eosinopoietic responses to schistosome worms and eggs. *International Journal for Parasitology*. July 2005;35(8):851-859.
 34. del Pozo JL, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R. The electricidal effect: reduction of *Staphylococcus* and *pseudomonas* biofilms by prolonged exposure to low-intensity electrical current. *Antimicrob Agents Chemother*. Jan 2009;53(1):41-45.
 35. Dellacasa-Lindberg I, Hitziger N, Barragan A. Localized recrudescence of *Toxoplasma* infections in the central nervous system of immunocompromised mice assessed by in vivo bioluminescence imaging. *Microbes and infection / Institut Pasteur*. Sep 2007;9(11):1291-1298.
 36. Demidova TN, Gad F, Zahra T, Francis KP, Hamblin MR. Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. *Journal of Photochemistry and Photobiology B: Biology*. 2005;In Press, Corrected Proof.
 37. Dennis A, Kudo T, Kruidenier L, Girard F, Crepin VF, MacDonald TT, Frankel G, Wiles S. The p50 subunit of NF-kappaB is critical for in vivo clearance of the noninvasive enteric pathogen *Citrobacter rodentium*. *Infect Immun*. Nov 2008;76(11):4978-4988.

38. Di Cristina M, Marocco D, Galizi R, Proietti C, Spaccapelo R, Crisanti A. Temporal and spatial distribution of *Toxoplasma gondii* differentiation into Bradyzoites and tissue cyst formation in vivo. *Infect Immun.* Aug 2008;76(8):3491-3501.
39. Disson O, Grayo S, Huillet E, Nikitas G, Langa-Vives F, Dussurget O, Ragon M, Le Monnier A, Babinet C, Cossart P, Lecuit M. Conjugated action of two species-specific invasion proteins for fetoplacental listeriosis. *Nature.* Oct 23 2008;455(7216):1114-1118.
40. Disson O, Nikitas G, Grayo S, Dussurget O, Cossart P, Lecuit M. Modeling human listeriosis in natural and genetically engineered animals. *Nature protocols.* 2009;4(6):799-810.
41. Doyle TC, Burns SM, Contag CH. In vivo bioluminescence imaging for integrated studies of infection. *Cellular Microbiology.* April 2004;6(4):303-317.
42. Doyle TC, Nawotka KA, Kawahara CB, Francis KP, Contag PR. Visualizing fungal infections in living mice using bioluminescent pathogenic *Candida albicans* strains transformed with the firefly luciferase gene. *Microbial Pathogenesis.* 2006;40(2):82-90.
43. Doyle TC, Nawotka KA, Purchio AF, Akin AR, Francis KP, Contag PR. Expression of firefly luciferase in *Candida albicans* and its use in the selection of stable transformants. *Microb Pathog.* Feb 2006;40(2):69-81.
44. Dunay IR, Sibley LD. Inflammatory Monocytes but not Neutrophils are Necessary to Control Infection with *Toxoplasma gondii* in Mice. *Infect Immun.* Feb 9 2010.
45. Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). *Cancer Immunol Immunother.* Feb 2009;58(2):209-220.
46. Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, Landmann R. Toll-like receptor 2-deficient mice are highly susceptible to *Streptococcus pneumoniae* meningitis because of reduced bacterial clearing and enhanced inflammation. *Journal of Infectious Disease.* September 2002;186(6):798-806.
47. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M, Basaraba RJ, Konig T, Schleicher U, Koo MS, Kaplan G, Fitzgerald KA, Tuomanen EI, Orme IM, Kanneganti TD, Bogdan C, Wynn TA, Murray PJ. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. *Nature immunology.* Dec 2008;9(12):1399-1406.
48. Engelsman AF, van der Mei HC, Busscher HJ, Ploeg RJ. Morphological aspects of surgical meshes as a risk factor for bacterial colonization. *The British journal of surgery.* Aug 2008;95(8):1051-1059.
49. Engelsman AF, van der Mei HC, Francis KP, Busscher HJ, Ploeg RJ, van Dam GM. Real time noninvasive monitoring of contaminating bacteria in a soft tissue implant infection model. *Journal of biomedical materials research.* Jan 2009;88(1):123-129.
50. Enjalbert B, Rachini A, Vedyappan G, Pietrella D, Spaccapelo R, Vecchiarelli A, Brown AJ, d'Enfert C. A multifunctional, synthetic *Gaussia princeps* luciferase reporter for live imaging of *Candida albicans* infections. *Infect Immun.* Aug 17

- 2009.
51. Evgin L, Vaha-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM. Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. *Mol Ther.* Feb 16 2010.
 52. Excoffon KJ, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK, Zabner J, Schaffer DV. Directed evolution of adeno-associated virus to an infectious respiratory virus. *Proc Natl Acad Sci U S A.* Mar 10 2009;106(10):3865-3870.
 53. Fang F, Flynn S, Li Y, Claesson MJ, van Pijkeren JP, Collins JK, van Sinderen D, O'Toole PW. Characterization of endogenous plasmids from *Lactobacillus salivarius* UCC118. *Applied and environmental microbiology.* May 2008;74(10):3216-3228.
 54. Fogar P, Navaglia F, Basso D, Zambon CF, Moserle L, Indraccolo S, Stranges A, Greco E, Fadi E, Padoan A, Pantano G, Sanzari MC, Pedrazzoli S, Montecucco C, Plebani M. Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy. *Cancer gene therapy.* Jul 17 2009.
 55. Foucault ML, Thomas L, Goussard S, Branchini BR, Grillot-Courvalin C. In vivo bioluminescence imaging for the study of intestinal colonization by *Escherichia coli* in mice. *Applied and environmental microbiology.* Jan 2010;76(1):264-274.
 56. Francis KP, Joh D, Bellinger-Kawahara C, Hawkinson MJ, Purchio TF, Contag PR. Monitoring bioluminescent *Staphylococcus aureus* infections in living mice using a novel luxABCDE construct. *Infect Immun.* June 2000;68(6):3594-3600.
 57. Francis KP, Yu J, Bellinger-Kawahara C, Joh D, Hawkinson MJ, Xiao G, Purchio TF, Caparon MG, Lipsitch M, Contag PR. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent *Streptococcus pneumoniae* transformed with a novel gram-positive lux transposon. *Infect Immun.* May 2001;69(5):3350-3358.
 58. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, Que I, Lowik C, Voshol PJ, den Boer MAM, van Duinen SG, Febbraio M, Mota MM, Waters AP. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. *PNAS.* July 28, 2005 2005:0503386102.
 59. Franke-Fayard B, Waters AP, Janse CJ. Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. *Nature protocols.* 2006;1(1):476-485.
 60. Gad F, Zahra T, Francis KP, Hasan T, Hamblin MR. Targeted photodynamic therapy of established soft-tissue infections in mice. *Photochemistry and Photobiology Science.* May 2004;3(5):451-458.
 61. Gal-Mor O, Gibson DL, Baluta D, Vallance BA, Finlay BB. A novel secretion pathway of *Salmonella enterica* acts as an antivirulence modulator during salmonellosis. *PLoS Pathog.* Apr 2008;4(4):e1000036.
 62. Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, Ryman KD. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. *J Virol.*

- Nov 2008;82(21):10634-10646.
63. Gibson DL, Ma C, Bergstrom KS, Huang JT, Man C, Vallance BA. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during *Citrobacter rodentium*-induced colitis. *Cell Microbiol.* Mar 2008;10(3):618-631.
 64. Gibson DL, Ma C, Rosenberger CM, Bergstrom KS, Valdez Y, Huang JT, Khan MA, Vallance BA. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during *Citrobacter rodentium*-induced colitis. *Cell Microbiol.* Feb 2008;10(2):388-403.
 65. Gill MB, Wright DE, Smith CM, May JS, Stevenson PG. Murid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization. *The Journal of general virology.* Jun 2009;90(Pt 6):1461-1470.
 66. Glomski IJ, Corre JP, Mock M, Goossens PL. Non-capsulated toxinogenic *Bacillus anthracis* present a specific growth and dissemination pattern in naive and PA-immune mice. *Infect Immun.* Jul 16 2007.
 67. Glomski IJ, Dumetz F, Jouvion G, Huerre MR, Mock M, Goossens PL. Inhaled non-capsulated *Bacillus anthracis* in A/J mice: nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting. *Microbes and infection / Institut Pasteur.* Oct 2008;10(12-13):1398-1404.
 68. Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL. Primary Involvement of Pharynx and Peyer's Patch in Inhalational and Intestinal Anthrax. *PLoS Pathog.* Jun 1 2007;3(6):e76.
 69. Glowalla E, Tosetti B, Kronke M, Krut O. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against *Staphylococcus aureus*. *Infect Immun.* Jul 2009;77(7):2719-2729.
 70. Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET. O antigen protects *Bordetella parapertussis* from complement. *Infect Immun.* Apr 2008;76(4):1774-1780.
 71. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez-Aseguinolaza G, Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. *The Journal of general virology.* Sep 2007;88(Pt 9):2473-2478.
 72. Greene IP, Lee EY, Prow N, Ngwang B, Griffin DE. Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. *Proc Natl Acad Sci U S A.* Mar 4 2008;105(9):3575-3580.
 73. Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Sarkioja M, Desmond RA, Kanerva A, Hemminki A. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. *Gene Ther.* Jun 2007;14(11):902-911.
 74. Hardy J, Chu P, Contag CH. Foci of *Listeria monocytogenes* persist in the bone marrow. *Disease models & mechanisms.* Jan-Feb 2009;2(1-2):39-46.
 75. Hardy J, Francis KP, DeBoer M, Chu P, Gibbs K, Contag CH. Extracellular replication of *Listeria monocytogenes* in the murine gall bladder. *Science.* February 2004;303(5659):851-853.

76. Hardy J, Margolis JJ, Contag CH. Induced biliary excretion of *Listeria monocytogenes*. *Infect Immun*. Mar 2006;74(3):1819-1827.
77. Harmache A, LeBerre M, Droineau S, Giovannini M, Bremont M. Bioluminescence Imaging of Live Infected Salmonids Reveals that the Fin Bases Are the Major Portal of Entry for Novirhabdovirus. *J. Virol*. April 1, 2006 2006;80(7):3655-3659.
78. Hemrajani C, Marches O, Wiles S, Girard F, Dennis A, Dziva F, Best A, Phillips AD, Berger CN, Mousnier A, Crepin VF, Kruidenier L, Woodward MJ, Stevens MP, La Ragione RM, MacDonald TT, Frankel G. Role of NleH, a type III secreted effector from attaching and effacing pathogens, in colonization of the bovine, ovine, and murine gut. *Infect Immun*. Nov 2008;76(11):4804-4813.
79. Henken S, Bohling J, Martens-Lobenhoffer J, Paton JC, Ogunniyi AD, Briles DE, Salisbury VC, Wedekind D, Bode-Boger SM, Welsh T, Bange FC, Welte T, Maus UA. Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. Feb 2010;54(2):707-717.
80. Herbert Tran EE, Goodrich-Blair H. CpxRA contributes to *Xenorhabdus nematophila* virulence through regulation of IrhA and modulation of insect immunity. *Applied and environmental microbiology*. Jun 2009;75(12):3998-4006.
81. Hesselink JW, van Dam GM. [Bioluminescence: the potential of a non-invasive bio-optical imaging technique and improvement of animal research]. *Tijdschr Diergeneeskd*. Apr 1 2007;132(7):244-250.
82. Hovav AH, Santosuosso M, Bivas-Benita M, Clair A, Cheng A, Elnekave M, Righi E, Chen T, Kashiwagi S, Panas MW, Xiang SH, Furmanov K, Letvin NL, Poznansky MC. X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens. *J Virol*. Nov 2009;83(21):10941-10950.
83. Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. *Cell Microbiol*. Oct 2007;9(10):2315-2322.
84. Hutchens M, Luker KE, Sottile P, Sonstein J, Lukacs NW, Nunez G, Curtis JL, Luker GD. TLR3 Increases Disease Morbidity and Mortality from Vaccinia Infection. *J Immunol*. Jan 1 2008;180(1):483-491.
85. Hwang S, Wu TT, Tong LM, Kim KS, Martinez-Guzman D, Colantonio AD, Uittenbogaart CH, Sun R. Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo. *J Virol*. Dec 2008;82(24):12498-12509.
86. Hyland KV, Asfaw SH, Olson CL, Daniels MD, Engman DM. Bioluminescent imaging of *Trypanosoma cruzi* infection. *International journal for parasitology*. Apr 25 2008.
87. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. *Journal of the National Cancer Institute*. Jun 3 2009;101(11):782-792.
88. Jia Q, Freeman ML, Yager EJ, McHardy I, Tong L, Martinez-Guzman D, Rickabaugh T, Hwang S, Blackman MA, Sun R, Wu TT. Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral

- latency. *J Virol.* Mar 2010;84(5):2453-2465.
89. Jiang SN, Phan TX, Nam TK, Nguyen VH, Kim HS, Bom HS, Choy HE, Hong Y, Min JJ. Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli-mediated Cytolytic Therapy and Radiotherapy. *Mol Ther.* Mar 2010;18(3):635-642.
 90. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. *J Virol.* Mar 2009;83(5):2067-2074.
 91. Jurcisek JA, Bookwalter JE, Baker BD, Fernandez S, Novotny LA, Munson RS, Jr., Bakaletz LO. The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. *Molecular microbiology.* Sep 2007;65(5):1288-1299.
 92. Kadurugamuwa JL, Francis KP. Bioluminescent imaging of bacterial biofilm infections in vivo. *Methods Mol Biol.* 2008;431:225-239.
 93. Kadurugamuwa JL, Modi K, Coquoz O, Rice B, Smith S, Contag PR, Purchio T. Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response. *Infect Immun.* Dec 2005;73(12):7836-7843.
 94. Kadurugamuwa JL, Modi K, Yu J, Francis KP, Orihuela C, Tuomanen E, Purchio AF, Contag PR. Noninvasive monitoring of pneumococcal meningitis and evaluation of treatment efficacy in an experimental mouse model. *Mol Imaging.* Apr-Jun 2005;4(2):137-142.
 95. Kadurugamuwa JL, Modi K, Yu J, Francis KP, Purchio T, Contag PR. Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice. *Infect Immun.* July 2005;73(7):3878-3887.
 96. Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, DeBoer M, Rubin M, Bellinger-Kawahara C, Parr Jr TR, Jr., Contag PR. Direct continuous method for monitoring biofilm infection in a mouse model. *Infect Immun.* February 2003;71(2):882-890.
 97. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Kimura R, Purchio T, Contag PR. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. *Antimicrob Agents Chemother.* October 2003;47(10):3130-3137.
 98. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Purchio TF, Contag PR. Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. *Antimicrob Agents Chemother.* June 2004;48(6):2283-2287.
 99. Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. *Vaccine.* Feb 11 2009;27(7):1040-1049.
 100. Karsi A, Lawrence ML. Broad host range fluorescence and bioluminescence expression vectors for Gram-negative bacteria. *Plasmid.* May 2007;57(3):286-295.
 101. Karsi A, Menanteau-Ledouble S, Lawrence ML. Development of bioluminescent

- Edwardsiella ictaluri for noninvasive disease monitoring. *FEMS Microbiology Letters*. 2006;260(2):216-223.
102. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, Han SH, Alitalo K, Koh GY. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. *Blood*. Apr 3 2009.
 103. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. *J Virol*. Feb 2010;84(3):1550-1562.
 104. Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. *Gene Ther*. May 2008;15(9):677-687.
 105. Kim MH, Liu W, Borjesson DL, Curry FR, Miller LS, Cheung AL, Liu FT, Isseroff RR, Simon SI. Dynamics of Neutrophil Infiltration during Cutaneous Wound Healing and Infection Using Fluorescence Imaging. *J Invest Dermatol*. Jan 10 2008.
 106. Kim SK, Karasov A, Boothroyd JC. Bradyzoite-specific surface antigen SRS9 plays a role in maintaining *Toxoplasma gondii* persistence in the brain and in host control of parasite replication in the intestine. *Infect Immun*. Apr 2007;75(4):1626-1634.
 107. Kirby AC, Beattie L, Maroof A, van Rooijen N, Kaye PM. SIGNR1-Negative Red Pulp Macrophages Protect against Acute Streptococcal Sepsis After *Leishmania donovani*-Induced Loss of Marginal Zone Macrophages. *The American journal of pathology*. Jul 30 2009.
 108. Kong Y, Subbian S, Cirillo SL, Cirillo JD. Application of optical imaging to study of extrapulmonary spread by tuberculosis. *Tuberculosis (Edinburgh, Scotland)*. Dec 2009;89 Suppl 1:S15-17.
 109. Kuklin NA, Pancari GD, Tobery TW, Cope L, Jackson J, Gill C, Overbye K, Francis KP, Yu J, Montgomery D, Anderson AS, McClements W, Jansen KU. Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models. *Antimicrob Agents Chemother*. September 2003;47(9):2740-2748.
 110. Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon G, Milon G, Lang T. Optimization of Topical Therapy for *Leishmania major* Localized Cutaneous Leishmaniasis Using a Reliable C57BL/6 Model. *PLoS neglected tropical diseases*. 2007;1(2):e34.
 111. Lecoeur H, Buffet PA, Milon G, Lang T. Early curative applications of the aminoglycoside WR279396 on an experimental *Leishmania major*-loaded cutaneous site do not impair the acquisition of immunity. *Antimicrob Agents Chemother*. Mar 2010;54(3):984-990.
 112. Leevy WM, Lambert TN, Johnson JR, Morris J, Smith BD. Quantum dot probes for bacteria distinguish *Escherichia coli* mutants and permit in vivo imaging. *Chemical communications (Cambridge, England)*. May 28 2008(20):2331-2333.
 113. Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N, Braun W, McCray PB, Jr., McChesney MB, Cattaneo R. Measles virus blind to its epithelial cell

receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. *The Journal of clinical investigation*. Jul 2008;118(7):2448-2458.

114. Li D, Gromov K, Soballe K, Puzas JE, O'Keefe RJ, Awad H, Drissi H, Schwarz EM. Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. *J Orthop Res*. Jan 2008;26(1):96-105.
115. Li HJ, Everts M, Yamamoto M, Curiel DT, Herschman HR. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. *Cancer research*. Jan 15 2009;69(2):554-564.
116. Li K, Thomasson D, Ketai L, Contag C, Pomper M, Wright M, Bray M. Potential applications of conventional and molecular imaging to biodefense research. *Clin Infect Dis*. May 2005;40(10):1471-1480.
117. Liu L, O'Conner P, Cotter PD, Hill C, Ross RP. Controlling *Listeria monocytogenes* in Cottage cheese through heterologous production of enterocin A by *Lactococcus lactis*. *Journal of applied microbiology*. Apr 2008;104(4):1059-1066.
118. Loving CL, Khurana T, Osorio M, Lee GM, Kelly VK, Stibitz S, Merkel TJ. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. *Infect Immun*. Jan 2009;77(1):255-265.
119. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnicka-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. *J Virol*. December 2002;76(23):12149-12161.
120. Luker GD, Leib DA. Luciferase real-time bioluminescence imaging for the study of viral pathogenesis. *Methods Mol Biol*. 2005;292:285-296.
121. Luker GD, Prior JL, Song J, Pica CM, Leib DA. Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors. *J Virol*. October 2003;77(20):11082-11093.
122. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. Bioluminescence imaging of vaccinia virus: Effects of interferon on viral replication and spread. *Virology*. Aug 8 2005.
123. Luker KE, Luker GD. Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitation. *Antiviral research*. Jun 2008;78(3):179-187.
124. Luker KE, Schultz T, Romine J, Leib DA, Luker GD. Transgenic reporter mouse for bioluminescence imaging of herpes simplex virus 1 infection in living mice. *Virology*. 2006;347(2):286-295.
125. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. *Proc Natl Acad Sci U S A*. February 2003;100(4):1966-1971.
126. Marques CP, Cheeran MC, Palmquist JM, Hu S, Urban SL, Lokensgard JR. Prolonged microglial cell activation and lymphocyte infiltration following

- experimental herpes encephalitis. *J Immunol.* Nov 1 2008;181(9):6417-6426.
127. Marr AK, Overhage J, Bains M, Hancock RE. The Lon protease of *Pseudomonas aeruginosa* is induced by aminoglycosides and is involved in biofilm formation and motility. *Microbiology (Reading, England)*. Feb 2007;153(Pt 2):474-482.
 128. Mason KM, Munson RS, Jr., Bakaletz LO. A mutation in the sap operon attenuates survival of nontypeable *Haemophilus influenzae* in a chinchilla model of otitis media. *Infect Immun.* January 2005;73(1):599-608.
 129. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. *Hepatology.* August 2003;38(2):503-508.
 130. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and *Streptococcus pneumoniae*. *J Infect Dis.* March 2003;187(6):1000-1009.
 131. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing *Streptococcus pneumoniae*. *PLoS Pathog.* Mar 2007;3(3):e28.
 132. Milho R, Smith CM, Marques S, Alenquer M, May JS, Gillet L, Gaspar M, Efsthathiou S, Simas JP, Stevenson PG. In vivo imaging of murid herpesvirus-4 infection. *The Journal of general virology.* Jan 2009;90(Pt 1):21-32.
 133. Min JJ, Kim HJ, Park JH, Moon S, Jeong JH, Hong YJ, Cho KO, Nam JH, Kim N, Park YK, Bom HS, Rhee JH, Choy HE. Noninvasive Real-time Imaging of Tumors and Metastases Using Tumor-targeting Light-emitting *Escherichia coli*. *Mol Imaging Biol.* Jan-Feb 2008;10(1):54-61.
 134. Min JJ, Nguyen VH, Kim HJ, Hong Y, Choy HE. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. *Nature protocols.* 2008;3(4):629-636.
 135. Miyahira AK, Shahangian A, Hwang S, Sun R, Cheng G. TANK-binding kinase-1 plays an important role during in vitro and in vivo type I IFN responses to DNA virus infections. *J Immunol.* Feb 15 2009;182(4):2248-2257.
 136. Mook-Kanamori BB, Rouse MS, Kang CI, van de Beek D, Steckelberg JM, Patel R. Daptomycin in experimental murine pneumococcal meningitis. *BMC infectious diseases.* 2009;9:50.
 137. Morin CE, Kaper JB. Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the *Vibrio cholerae* vaccine strain CVD 103-HgR. *FEMS immunology and medical microbiology.* Oct 2009;57(1):69-79.
 138. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* peritonitis in mice as measured with bioluminescent bacteria. *Antimicrob Agents Chemother.* May 2007;51(5):1787-1794.
 139. Mulcahy H, O'Callaghan J, O'Grady EP, Macia MD, Borrell N, Gomez C, Casey PG, Hill C, Adams C, Gahan CG, Oliver A, O'Gara F. *Pseudomonas aeruginosa* RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation. *Infect Immun.* Feb 2008;76(2):632-638.

140. Mwakingwe A, Ting LM, Hochman S, Chen J, Sinnis P, Kim K. Noninvasive real-time monitoring of liver-stage development of bioluminescent *Plasmodium* parasites. *J Infect Dis.* Nov 1 2009;200(9):1470-1478.
141. Nagamune K, Hicks LM, Fux B, Brossier F, Chini EN, Sibley LD. Abscisic acid controls calcium-dependent egress and development in *Toxoplasma gondii*. *Nature.* Jan 10 2008;451(7175):207-210.
142. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, Easton DM, Mayer ML, Mullaly SC, Kindrachuk J, Jenssen H, Hancock RE. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. *J Immunol.* Mar 1 2010;184(5):2539-2550.
143. Notebaert S, Carlsen H, Janssen D, Vandenabeele P, Blomhoff R, Meyer E. In vivo imaging of NF-kappaB activity during *Escherichia coli*-induced mammary gland infection. *Cell Microbiol.* Jun 2008;10(6):1249-1258.
144. Novotny LA, Mason KM, Bakaletz LO. Development of a chinchilla model to allow direct, continuous, biophotonic imaging of bioluminescent nontypeable *Haemophilus influenzae* during experimental otitis media. *Infect Immun.* January 2005;73(1):609-611.
145. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A, Lawrence TS. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model *Gene Therapy.* July 2002;9(13):844-849.
146. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O'Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. *PLoS Pathog.* 2008;4(8):e1000112.
147. Ogunniyi AD, Paton JC, Kirby AC, McCullers JA, Cook J, Hyodo M, Hayakawa Y, Karaolis DK. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. *Vaccine.* Aug 26 2008;26(36):4676-4685.
148. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. *J Infect Dis.* November 2004;190(9):1661-1669.
149. Orihuela CJ, Gao G, McGee M, Yu J, Francis KP, Tuomanen E. Organ-specific models of *Streptococcus pneumoniae* disease. *Scand J Infect Dis.* 2003;35(9):647-652.
150. Owen SJ, Batzloff M, Chehrehasa F, Meedeniya A, Casart Y, Logue CA, Hirst RG, Peak IR, Mackay-Sim A, Beacham IR. Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for *Burkholderia pseudomallei* in murine melioidosis. *J Infect Dis.* Jun 15 2009;199(12):1761-1770.
151. Park HS, Francis KP, Yu J, Cleary PP. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. *J Immunol.* September 2003;171(5):2532-2537.
152. Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. *J Virol.* Jan 2009;83(1):479-483.

153. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, Costantino P, Mosci P, d'Enfert C, Rappuoli R, Cassone A, Vecchiarelli A. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. *Vaccine*. Feb 17 2010;28(7):1717-1725.
154. Piliponsky AM, Chen CC, Grimbaldston MA, Burns-Guydish SM, Hardy J, Kalesnikoff J, Contag CH, Tsai M, Galli SJ. Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. *The American journal of pathology*. Feb 2010;176(2):926-938.
155. Ploemen IH, Prudencio M, Douradinha BG, Ramesar J, Fonager J, van Gemert GJ, Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG, Mota MM, Waters AP, Que I, Lowik CW, Khan SM, Janse CJ, Franke-Fayard BM. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. *PloS one*. 2009;4(11):e7881.
156. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA. Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP. *The Journal of biological chemistry*. Apr 10 2009;284(15):9892-9898.
157. Rajashekara G, Glover DA, Krepps M, Splitter GA. Temporal analysis of pathogenic events in virulent and avirulent *Brucella melitensis* infections. *Cellular Microbiology*. 2005;7(10):1459-1473.
158. Rambow-Larsen AA, Rajashekara G, Petersen E, Splitter G. Putative quorum-sensing regulator BlxR of *Brucella melitensis* regulates virulence factors including the type IV secretion system and flagella. *Journal of bacteriology*. May 2008;190(9):3274-3282.
159. Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, Chignard M. Control of *Pseudomonas aeruginosa* in the lung requires the recognition of either lipopolysaccharide or flagellin. *J Immunol*. Jul 1 2008;181(1):586-592.
160. Randall LM, Amante FH, McSweeney KA, Zhou Y, Stanley AC, Haque A, Jones MK, Hill GR, Boyle GM, Engwerda CR. Common strategies to prevent and modulate experimental cerebral malaria in mouse strains with different susceptibilities. *Infect Immun*. Jul 2008;76(7):3312-3320.
161. Raska M, Moldoveanu Z, Novak J, Hel Z, Novak L, Bozja J, Compans RW, Yang C, Mestecky J. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. *Vaccine*. Mar 17 2008;26(12):1541-1551.
162. Riedel CU, Monk IR, Casey PG, Waidmann MS, Gahan CG, Hill C. AgrD-dependent quorum sensing affects biofilm formation, invasion, virulence and global gene expression profiles in *Listeria monocytogenes*. *Molecular microbiology*. Mar 2009;71(5):1177-1189.
163. Rivera A, Collins N, Stephan MT, Lipuma L, Leiner I, Pamer EG. Aberrant tissue localization of fungus-specific CD4+ T cells in IL-10-deficient mice. *J Immunol*. Jul 1 2009;183(1):631-641.
164. Rivera R, Hutchens M, Luker KE, Sonstein J, Curtis JL, Luker GD. Murine alveolar macrophages limit replication of vaccinia virus. *Virology*. Feb 26 2007.

165. Rocchetta HL, Boylan CJ, Foley JW, Iversen PW, LeTourneau DL, McMillian CL, Contag PR, Jenkins DE, Parr TR, Jr. Validation of a noninvasive, real-time imaging technology using bioluminescent *Escherichia coli* in the neutropenic mouse thigh model of infection. *Antimicrob Agents Chemother.* January 2001;45(1):129-137.
166. Ryman KD, Gardner CL, Meier KC, Biron CA, Johnston RE, Klimstra WB. Early restriction of alphavirus replication and dissemination contributes to age-dependent attenuation of systemic hyperinflammatory disease. *The Journal of general virology.* Feb 2007;88(Pt 2):518-529.
167. Saeij JP, Arrizabalaga G, Boothroyd JC. A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in *Toxoplasma gondii* persistence. *Infect Immun.* Jun 2008;76(6):2402-2410.
168. Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC. Bioluminescence imaging of *Toxoplasma gondii* infection in living mice reveals dramatic differences between strains. *Infect Immun.* February 2005;73(2):695-702.
169. Samir J, Serge M. Monitoring of bactericidal action of laser by in vivo imaging of bioluminescent *E. coli* in a cutaneous wound infection. *Lasers in Medical Science.* 2006;V21(3):153-159.
170. Sanz P, Teel LD, Alem F, Carvalho HM, Darnell SC, O'Brien AD. Detection of *Bacillus anthracis* spore germination in vivo by bioluminescence imaging. *Infect Immun.* Jan 14 2008.
171. Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V. A novel human Her-2/neu chimeric molecule expressed by *Listeria monocytogenes* can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. *Clin Cancer Res.* Feb 1 2009;15(3):924-932.
172. Sedgley C, Applegate B, Nagel A, Hall D. Real-time imaging and quantification of bioluminescent bacteria in root canals in vitro. *J Endod.* December 2004;30(12):893-898.
173. Sedgley CM, Nagel AC, Hall D, Applegate B. Influence of irrigant needle depth in removing bioluminescent bacteria inoculated into instrumented root canals using real-time imaging in vitro. *Int Endod J.* February 2005;38(2):97-104.
174. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, Dennis CG, Vethanayagam RR, Yull FE, Capitano M, Wallace PK, Minderman H, Christman JW, Sporn MB, Chan J, Vinh DC, Holland SM, Romani LR, Gaffen SL, Freeman ML, Blackwell TS. NADPH oxidase limits innate immune responses in the lungs in mice. *PLoS one.* 2010;5(3):e9631.
175. Sheel M, Pandey M, Good MF, Batzloff MR. Passive protection in mice challenged with a recombinant bioluminescent M49 group A streptococcus strain: Correlation between bioluminescence and bacterial burden. *Clin Vaccine Immunol.* Nov 4 2009.
176. Sheel M, Pandey M, Good MF, Batzloff MR. Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain. *Clin Vaccine Immunol.* Jan

- 2010;17(1):127-133.
177. Shlomai A, Paran N, Shaul Y. PGC-1alpha controls hepatitis B virus through nutritional signals. *Proc Natl Acad Sci U S A*. Oct 24 2006;103(43):16003-16008.
 178. Skelding KA, Barry RD, Shafren DR. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. *Breast cancer research and treatment*. Jan 2009;113(1):21-30.
 179. Smith PG, Oakley F, Fernandez M, Mann DA, Lemoine NR, Whitehouse A. Herpesvirus saimiri-based vector biodistribution using noninvasive optical imaging. 2005.
 180. Spaccapelo R, Janse CJ, Caterbi S, Franke-Fayard B, Bonilla JA, Syphard LM, Di Cristina M, Dottorini T, Savarino A, Cassone A, Bistoni F, Waters AP, Dame JB, Crisanti A. Plasmepsin 4-deficient *Plasmodium berghei* are virulence attenuated and induce protective immunity against experimental malaria. *The American journal of pathology*. Jan 2010;176(1):205-217.
 181. Steinhuber A, Landmann R, Goerke C, Wolz C, Fluckiger U. Bioluminescence imaging to study the promoter activity of hla of *Staphylococcus aureus* in vitro and in vivo. *Int J Med Microbiol*. Oct 2008;298(7-8):599-605.
 182. Symonds EL, Riedel CU, O'Mahony D, Laphorne S, O'Mahony L, Shanahan F. Involvement of T helper type 17 and regulatory T cell activity in *Citrobacter rodentium* invasion and inflammatory damage. *Clinical and experimental immunology*. Jul 2009;157(1):148-154.
 183. Tamguney G, Francis KP, Giles K, Lemus A, Dearmond SJ, Prusiner SB. Measuring prions by bioluminescence imaging. *Proc Natl Acad Sci U S A*. Aug 17 2009.
 184. Valuckaite V, Zaborina O, Long J, Hauer-Jensen M, Wang J, Holbrook C, Zaborin A, Drabik K, Katdare M, Mauceri H, Weichselbaum R, Firestone MA, Lee KY, Chang EB, Matthews J, Alverdy JC. Oral PEG 15-20 protects the intestine against radiation: role of lipid rafts. *Am J Physiol Gastrointest Liver Physiol*. Dec 2009;297(6):G1041-1052.
 185. Vodnala SK, Ferella M, Lunden-Miguel H, Betha E, van Reet N, Amin DN, Oberg B, Andersson B, Kristensson K, Wigzell H, Rottenberg ME. Preclinical assessment of the treatment of second-stage african trypanosomiasis with cordycepin and deoxycoformycin. *PLoS neglected tropical diseases*. 2009;3(8):e495.
 186. von Kockritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norrby-Teglund A, Rohde M, Medina E. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. *Blood*. Mar 15 2008;111(6):3070-3080.
 187. von Kockritz-Blickwede M, Rohde M, Oehmcke S, Miller LS, Cheung AL, Herwald H, Foster S, Medina E. Immunological mechanisms underlying the genetic predisposition to severe *Staphylococcus aureus* infection in the mouse model. *The American journal of pathology*. Dec 2008;173(6):1657-1668.
 188. Vuong C, Kocianova S, Yu J, Kadurugamuwa JL, Otto M. Development of real-time in vivo imaging of device-related *Staphylococcus epidermidis* infection in

- mice and influence of animal immune status on susceptibility to infection. *J Infect Dis.* Jul 15 2008;198(2):258-261.
189. Wang J, Barke RA, Charboneau R, Schwendener R, Roy S. Morphine induces defects in early response of alveolar macrophages to *Streptococcus pneumoniae* by modulating TLR9-NF-kappa B signaling. *J Immunol.* Mar 1 2008;180(5):3594-3600.
 190. Watson D, Sleator RD, Casey PG, Hill C, Gahan CG. Specific osmolyte transporters mediate bile tolerance in *Listeria monocytogenes*. *Infect Immun.* Nov 2009;77(11):4895-4904.
 191. Watson D, Sleator RD, Hill C, Gahan CG. Enhancing bile tolerance improves survival and persistence of *Bifidobacterium* and *Lactococcus* in the murine gastrointestinal tract. *BMC microbiology.* 2008;8:176.
 192. White AP, Gibson DL, Grassl GA, Kay WW, Finlay BB, Vallance BA, Surette MG. Aggregation via the red, dry, and rough morphotype is not a virulence adaptation in *Salmonella enterica* serovar Typhimurium. *Infect Immun.* Mar 2008;76(3):1048-1058.
 193. Wiles S, Clare S, Harker J, Huett A, Young D, Dougan G, Frankel G. Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen *Citrobacter rodentium*. *Cell Microbiol.* October 2004;6(10):963-972.
 194. Wiles S, Pickard KM, Peng K, MacDonald TT, Frankel G. In Vivo Bioluminescence Imaging of the Murine Pathogen *Citrobacter rodentium*. *Infect. Immun.* September 1, 2006 2006;74(9):5391-5396.
 195. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. *Nature materials.* Jun 2009;8(6):526-533.
 196. Wu W, Lockhart SR, Pujol C, Srikantha T, Soll DR. Heterozygosity of genes on the sex chromosome regulates *Candida albicans* virulence. *Molecular microbiology.* Jun 2007;64(6):1587-1604.
 197. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat *Staphylococcus aureus* endocarditis model. *Antimicrob Agents Chemother.* January 2005;49(1):380-387.
 198. Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL. Monitoring in vivo fitness of rifampicin-resistant *Staphylococcus aureus* mutants in a mouse biofilm infection model. *J Antimicrob Chemother.* April 2005;55(4):528-534.
 199. Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. *J Virol.* Oct 2009;83(20):10437-10447.
 200. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglian SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MR. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell

- transplantation. *Nature medicine*. Sep 2006;12(9):1039-1047.
201. Zhang Z, Huang Y, Zhu H. A highly efficient protocol of generating and analyzing VZV ORF deletion mutants based on a newly developed luciferase VZV BAC system. *Journal of virological methods*. Mar 2008;148(1-2):197-204.
 202. Zhang Z, Rowe J, Wang W, Sommer M, Arvin A, Moffat J, Zhu H. Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. *J Virol*. Sep 2007;81(17):9024-9033.
 203. Zhu Q, Oei Y, Mendel DB, Garrett EN, Patawaran MB, Hollenbach PW, Aukerman SL, Weiner AJ. Novel Robust Hepatitis C Virus Mouse Efficacy Model. *Antimicrob. Agents Chemother*. October 1, 2006 2006;50(10):3260-3268.
 204. Zinn KR, Chaudhuri TR, Szafran AA, O'Quinn D, Weaver C, Dugger K, Lamar D, Kesterson RA, Wang X, Frank SJ. Noninvasive bioluminescence imaging in small animals. *ILAR journal / National Research Council, Institute of Laboratory Animal Resources*. 2008;49(1):103-115.